文献速递哮喘

儿童哮喘患者起始孟鲁司特后的神经精神诊断

Neuropsychiatric diagnoses after montelukast initiation in paediatric patients with asthma.
PubMed 文献 · Thorax · 2024-12-23

孟鲁司特组任何神经精神结局发生率较高(每1000人71例 vs 54例;RR 1.32,95%CI 1.25-1.39),其中睡眠障碍风险最高(RR 1.63,95%CI 1.50-1.77),焦虑和情绪障碍风险亦升高。

要点

  • 孟鲁司特辅助治疗与1年内任何神经精神诊断风险升高相关(RR 1.32)。
  • 睡眠障碍超额风险最高(RR 1.63),焦虑和情绪障碍风险亦升高。
  • 1年需伤害人数(NNH)为58例,睡眠障碍NNH为85例。

核心结论

  • 在使用ICS的哮喘儿童和青少年中,孟鲁司特辅助治疗与神经精神结局发生率升高相关。

研究设计与样本

  • 倾向评分匹配队列研究,使用2015-2019年美国TriNetX Analytics Network电子健康记录。

主要发现

  • 孟鲁司特组任何神经精神结局发生率为每1000人71例,未暴露组为54例(RR 1.32,95%CI 1.25-1.39)。
  • 绝对风险增加每100人1.71(95%CI 1.44-1.98),1年NNH为58例(95%CI 51-69)。
  • 睡眠障碍RR 1.63(95%CI 1.50-1.77),绝对风险增加每100人1.17(95%CI 1.00-1.33),NNH 85例(95%CI 75-100)。
  • 焦虑障碍RR 1.16(95%CI 1.08-1.24),情绪障碍RR 1.16(95%CI 1.05-1.29)。

临床怎么用

  • 对使用ICS的哮喘儿童和青少年处方孟鲁司特时,应关注神经精神不良反应风险。
  • 用药期间需监测睡眠障碍、焦虑和情绪障碍等神经精神症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The evidence base on montelukast-associated adverse outcomes is inconclusive in children and young persons (CYP) with asthma. We aimed to investigate 1-year incidence of neuropsychiatric diagnoses after initiation of montelukast as an adjunct therapy to inhaled corticosteroids (ICSs) in CYP aged 3-17 years with asthma. METHODS: This propensity score matched cohort study was conducted using electronic health records between 2015 and 2019 in the TriNetX Analytics Network patient repository in the USA. Neuropsychiatric diagnoses were identified using the International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. We estimated risk ratios (RRs), absolute risk increase (ARI) and number needed to harm (NNH) with 95% CIs. FINDINGS: The mean age (SD) at index prescription in the 107 384 CYP with asthma was 8.7 (4.0) years (93 461 (87%) mild to moderate asthma; 62 301 (58%) male; 53 485 (50%) white; 33 107 (31%) black/African American). Montelukast was associated with excess incidence of any neuropsychiatric outcome (71 per 1000 persons with montelukast and 54 per 1000 persons with no montelukast; RR 1.32 (95% CI 1.25 to 1.39); ARI per 100 persons, 1.71 (95% CI 1.44 to 1.98); 1-year NNH, 58 patients (95% CI 51 to 69)). The highest excess risk in the montelukast group was for sleep disorders (RR 1.63 (95% CI 1.50 to 1.77); ARI per 100 persons 1.17 (95% CI 1.00 to 1.33); NNH, 85 patients (95% CI 75 to 100)). Montelukast use was also associated with excess incidence of anxiety disorders (RR 1.16 (95% CI 1.08 to 1.24)) and mood disorders (RR 1.16 (95% CI 1.05 to 1.29)). CONCLUSIONS: In CYP with asthma who were treated with ICSs, adjunct treatment with montelukast was associated with a higher incidence of neuropsychiatric outcomes compared with those who were not exposed to montelukast.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Paljarvi T, Forton JT, Thompson C, et al. Neuropsychiatric diagnoses after montelukast initiation in paediatric patients with asthma. Thorax. 2024. PMID: 39578088. doi:10.1136/thorax-2024-221590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。